Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Richard Eek"'
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Autor:
William Reed, Richard Eek, Andrew Nicol, Radha Prathikanti, Rebecca Elstrom, Hannah Rose, Michael F. Leahy, Aileen Cohen, Jingjing Schneider, Xavier Badoux, Constantine S. Tam, Nicholas Wickham, H. Miles Prince, Sushrut Patil, Jane Huang, Hang Quach, Ian W. Flinn
Publikováno v:
Blood Adv
Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early effic
Autor:
Mengjun Wang, Jehan Dupuis, T. Lamy, Andrew Davies, Carlos Panizo, Tadeusz Robak, Eric N. Jacobsen, Lucie Oberic, S. Le Gouill, Simon Rule, Richard Eek, Arnon P. Kater, Monika Długosz-Danecka, O. Casasnovas, Roser Calvo, J.K. Doorduijn, Preetesh Jain, F. Morschhauser, Stephen D. Smith, Lin Tao, Bhavana Shah, Ghandi Damaj, P. L. Zinzani, Andre Goy
Publikováno v:
Hematological Oncology. 39
Autor:
Warwick Benson, Tracey Gerber, Meaghan Wall, K. M. Taylor, Devendra K Hiwase, Piers Blombery, Richard Eek, Melita Kenealy, Diana Zannino, John F. Seymour, Marlyse A. Debrincat, Steve Jong, Mark P. Hertzberg, Daniela Zantomio, Will Stevenson, Ilona Cunningham
Publikováno v:
Haematologica
Standard treatment for higher risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast acute myeloid leukemia (AML) is azacitidine. In single arm studies, the addition of lenalidomide had been suggested to improve ou
Publikováno v:
Late-breaking abstracts.
Background The endothelin B receptor (ETBR) is upregulated in many types of cancer and is associated with poor overall survival and a paucity of TILs (tumor infiltrating lymphocytes).1 The ETBR prevents T-cell extravasation and tumor infiltration by
Autor:
Pier Luigi Zinzani, Michael Wang, Andre Goy, Stephen D. Smith, Bijal D. Shah, Steven Le Gouill, Thierry Lamy, Priti Patel, Raquel Izumi, Arnon P. Kater, Monika Długosz-Danecka, Lucie Oberic, Andrew Davies, Jehan Dupuis, Tadeusz Robak, Simon Rule, Richard Eek, Jeanette K. Doorduijn, Melanie M. Frigault, Gandhi Damaj, Ming Yin, Carlos Panizo, Olivier Casasnovas, Eric D. Jacobsen, Preetesh Jain, Franck Morschhauser, Dorothy Nguyen
Publikováno v:
Leukemia
Leukemia, 2019, Leukemia, 33, pp.2762-2766. ⟨10.1038/s41375-019-0575-9⟩
Dadun. Depósito Académico Digital de la Universidad de Navarra
Consejo Superior de Investigaciones Científicas (CSIC)
Leukemia, 33(11), 2762-2766. Nature Publishing Group
Leukemia, 2019, Leukemia, 33, pp.2762-2766. ⟨10.1038/s41375-019-0575-9⟩
Dadun. Depósito Académico Digital de la Universidad de Navarra
Consejo Superior de Investigaciones Científicas (CSIC)
Leukemia, 33(11), 2762-2766. Nature Publishing Group
Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b787d4150f40958ac690c8e86b8cee63
https://eprints.soton.ac.uk/436221/
https://eprints.soton.ac.uk/436221/
Autor:
Wee Joo Chng, Bradley Augustson, Brian G.M. Durie, Jeffrey Sy. Huang, Hang Quach, Noemi Horvath, Yoon Sung Soo, Kim Ki-Hyun, Jae Hoon Lee, Jane Estell, Je-Jung Lee, Simon J. Harrison, Soo Mee Bang, Rajeev Rajagopal, Philip Campbell, Nichloas Murphy, Richard Eek, Belinda Butcher
Publikováno v:
Blood. 136:39-40
Background: The combination of carfilzomib with immunomodulatory drugs (IMiDs) and dexamethasone is active in multiple myeloma (MM). Carfilzomib, thalidomide, and dexamethasone (KTd) has been studied in upfront MM treatment but has not been studied i
Autor:
Steven Le Gouill, Carlos Panizo, Tadeusz Robak, Michael Wang, Thierry Lamy, Monika Długosz-Danecka, Pier Luigi Zinzani, Bijal D. Shah, Rene-Olivier Casasnovas, Lucie Oberic, Priti Patel, Simon Rule, Richard Eek, Stephen D. Smith, Lin Tao, Gandhi Damaj, Jeanette K. Doorduijn, Andre Goy, Andrew Davies, Preetesh Jain, Franck Morschhauser, Jehan Dupuis, Eric N. Jacobsen, Graham Brock, Arnon P. Kater
Publikováno v:
Blood. 136:38-39
Background: Acalabrutinib (acala) is a next-generation, highly selective, covalent Bruton tyrosine kinase (BTK) inhibitor approved for patients (pts) with mantle cell lymphoma (MCL) who have received ≥1 prior therapy. The efficacy and safety of aca
Autor:
Catherine Shannon, Janice M. Lu, Sulan Yao, Haeseong Park, Gang Xia, Xichun Hu, Amelia McCartney, Jinchun Yan, Katharine Cuff, Dongmei Ji, Gaozhun Xiong, Yanping Ji, Sara A. Hurvitz, Sophia Frentzas, Joyce O'Shaughnessy, Matt Li, George Thomas Budd, Weina Shen, Jian Zhang, Richard Eek
Publikováno v:
Journal of Clinical Oncology. 39:1038-1038
1038 Background: ARX788 is a site-specific, homogeneous, and highly stable ADC. The payload AS269 is conjugated to the synthetic amino acids para-acetylphenylalanine (pAF) in a humanized anti-HER2 mAb. ARX788 demonstrated promising activity in HER2-p
Autor:
Georgia J. McCaughan, M Hasib Sidiqi, Richard Eek, Andrew Lim, Michael Low, Nicholas E. Murphy, Jessica M Heenan, Peter Mollee, David Routledge, Jane Estell, Peter Browlett, Hock Choong Lai, Rajeev Rajagopal, James D'Rozario, William Renwick, Anna Kalff, Hang Quach, Masa Lasica, Philip Campbell, Georgina Huan
Publikováno v:
Journal of Clinical Oncology. 39:TPS8055-TPS8055
TPS8055 Background: Len maintenance post ASCT is standard of care for patients (pts) with NDMM. Deep responses (CR or better) post ASCT correlates with better progression free survival (PFS). In a meta-analysis of len maintenance post ASCT (McCarthy